Bli medlem
Bli medlem

Du är här


Karolinska Development portfolio company Promimic and Danco announce completion of US production line for HAnano Surface medical implant coating

Karolinska Development portfolio company Promimic and Danco announce completion
of US production line for HAnano Surface medical implant coating

STOCKHOLM - October 19, 2016. Karolinska Development AB (Nasdaq Stockholm:
KDEV) today announces that its portfolio company Promimic AB, an innovative
biomaterials company, and its partner Danco Anodizing have successfully
completed the production line in the USA for Promimic's HAnano Surface coating
for orthopedic and dental implants

Details from the Promimic press release follow:

Promimic and Danco entered a strategic partnership in March 2016 under which
Danco became the preferred process partner for Promimic for the USA and China
medical implant markets. Danco has also invested in the production line for
HAnano Surface at its manufacturing facility in Warsaw, IN, USA.

Promimic’s HAnano Surface represents a new era of implant surfaces, based on
bio-mimicking synthetic bone minerals. The unique and proprietary HAnano
Surface is only 20 nanometers thin and can be applied to almost any implant
material. It has been shown to increase the anchoring strength and integration
of medical implants with surrounding bone tissue in over 20 pre-clinical
studies. The HAnano Surface is already in clinical use on dental implants in
Brazil. Promimic recently raised SEK 23.8 million to establish its own sales
operations in the US.

Danco Anodizing has been a leader in the processing of titanium, stainless
steel, and aluminum parts for the orthopedic industry since 1992 and works with
many of the leading orthopaedic implant companies on the US market.

Ulf Brogren, Promimic CEO, said: “We are excited to finalize the production
line with our strategic partner Danco. We firmly believe this will further
increase already strong interest in Promimic’s innovative technology from
implant companies supplying the US and Chinese markets. The new US production
site will facilitate easy access and minimal investments for our customers,
giving them flexibility and a faster route to market.”

Dean Zentz, Danco VP Operations, said: “Danco is pleased to be a part of this
exciting venture with Promimic and is confident Promimic’s technology and our
manufacturing expertise will offer our customers an improved solution for
medical implants.”

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail:

Christian Tange, CFO, Karolinska Development AB

Phone: +46 73 712 14 30, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson

Phone: +44 20 7638 9571; e-mail:


About Promimic AB

Promimic, based in Gothenburg, Sweden, develops and markets products within
nano-materials for innovative surface treatments. Promimic has developed;
HAnano Surface that has been shown to speed up and improve the anchoring of
implants in bone. The innovative HAnano Surface is licensed to dental and
orthopaedic implant companies

Contact: Ulf Brogren, CEO

Phone: +46 730 79 42 07; e-mail:

About Danco Anodizing Inc

Established in 1971 with headquarters in Arcadia, CA and supporting facilities
in Ontario, CA, Santa Ana, CA, Warsaw, IN, and Changzhou, China, Danco provides
technically superior surface treatments to many diverse industries, including
the medical device industry. Danco-Warsaw and Danco-China are ISO 13485, and
have extensive process validations to support customer and regulatory

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying medical innovation and
investing in the creation and growth of companies developing these assets into
differentiated products that will make a difference to patients’ lives and
provide an attractive return on investment to its shareholders.

Karolinska Development has access to world-class medical innovations at leading
universities and research institutes in the Nordic region, including the
Karolinska Institutet. The Company aims to build companies around innovative
products and technologies, supported by experienced management teams and
advisers, and co-funded by specialist international life science investors, to
provide the greatest chance of success.

Karolinska Development’s portfolio comprises 10 companies focusing on the
development of innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by a team of investment professionals with strong investment
backgrounds, experienced company builders and entrepreneurs, with access to a
strong global network. For more information, please visit

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.